No Data
Is Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Recent Performance Underpinned By Weak Financials?
Hendi Pharmaceutical (301211.SZ): Ibuprofen sustained-release capsules have obtained the Pharmaceutical registration certificate.
On January 20, Gelonghui reported that Hendy Pharmaceutical (301211.SZ) announced that it recently received the "Drug Registration Certificate" for ibuprofen sustained-release capsules from the National Medical Products Administration. Ibuprofen sustained-release capsules are non-steroidal anti-inflammatory drugs that exert antipyretic, analgesic, and anti-inflammatory effects by inhibiting the synthesis of prostaglandins. Ibuprofen sustained-release capsules are often used to treat mild to moderate pain such as headaches, joint pain, toothaches, muscle pain, and neuropathic pain; they can also be used for fever caused by colds. Ibuprofen sustained-release capsules are sustained-release formulations that slowly release the drug in the body, leading to a slow onset of action and a long duration, which can last for 12 hours.
Private Companies Are Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) Biggest Owners and Were Hit After Market Cap Dropped CN¥415m
Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?
Hendy Pharmaceuticals: third quarter report 2024
Hengdi Pharmaceutical (301211.SZ): The net income for the first three quarters was 74.6615 million yuan, a year-on-year decrease of 48.34%.
On October 27, Hengdi Pharmaceutical (301211.SZ) announced that in the first three quarters of 2024, it achieved revenue of 0.334 billion yuan, a decrease of 38.43% year-on-year; the net income attributable to shareholders of the listed company was 74.6615 million yuan, a decrease of 48.34%, with a basic earnings per share of 0.26 yuan.